Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

EPO Patent Publication: Fish Skin Collagen Peptides Composition and Drug Use

The European Patent Office has published patent application EP3532491A1 concerning the composition of fish skin collagen peptides and their use as a drug. The publication details the applicants and inventors associated with this patent.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent EP3515945A1: Anti-STEAP2 Antibodies, Drug Conjugates, Uses

The European Patent Office has published patent application EP3515945A1 concerning anti-STEAP2 antibodies, antibody-drug conjugates, and their uses, filed by Regeneron Pharmaceuticals, Inc. The patent application details specific molecular entities and their therapeutic applications, particularly in oncology.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Publication: BAFF-R Targeted CAR T-cells

The European Patent Office published patent application EP3464371A1 on March 11, 2026, concerning BAFF-R targeted chimeric antigen receptor-modified T-cells and their uses. The patent application lists City of Hope and The University of Texas System as applicants.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Bulletin: Immune Stimulating Antibodies Against IL-2 Fusion Proteins

The European Patent Office has published patent application EP3402819A1 concerning immune-stimulating humanized monoclonal antibodies against human interleukin-2 and fusion proteins thereof. The patent application was published on March 11, 2026, by applicant Universität Zürich.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent EP3356393A1: Chimeric Proteins for Extracellular Domains

The European Patent Office has published patent application EP3356393A1 concerning chimeric proteins for adjoining extracellular domains. The patent, filed by Kopfkino IP, LLC, details compositions and methods related to these protein structures.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Bulletin: Antigen-binding proteins targeting CD56

The European Patent Office has published patent application EP3328994A1 concerning antigen-binding proteins targeting CD56 and their uses. The patent was filed by Memorial Sloan-Kettering Cancer Center and the U.S. Department of Health and Human Services.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Publication EP3390433A1: Novel Cytokine Fusion Proteins

The European Patent Office has published patent application EP3390433A1 for BioNTech SE, detailing novel cytokine fusion proteins. This publication is part of the EPO Bulletin and relates to advancements in peptide technology.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Bulletin - Antibody Molecules Binding CD45

The European Patent Office (EPO) has published patent application EP3322729A1 concerning antibody molecules that bind CD45. The publication details the applicant, UCB Biopharma SRL, and the inventors, along with International Patent Classification codes related to peptides, antibodies, and therapeutic uses.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

Patent EP2919859A1: Collagen with Metallic Anticancer Agents

The European Patent Office has published patent application EP2919859A1, filed by MIMEDX Group Inc. The patent describes cross-linked collagen comprising metallic anticancer agents. The publication date is March 11, 2026.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

CLC Intent to Use Trademark Application

The USPTO has received an Intent to Use trademark application (TM98259610) from CLC for digital media and entertainment production services. The application was filed on November 7, 2023.

Routine Notice Intellectual Property

Showing 13011–13020 of 37,364 changes

1 1300 1301 1302 1303 1304 3737

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.